158.44  -0.39 (-0.25%)		07-30 16:00
Open: 157.145 High: 158.54 Volume: 1,991,586		Pre. Close: 158.83 Low: 156.46 Market Cap: 301,149(M)

Short term
Mid term
Targets	6-month :	187.54	1-year :	219.05
Resists	First :	160.57	Second :	187.54
Pivot price	154.39
Supports	First :	153.62	Second :	149.33
MAs	MA(5) :	157.64	MA(20) :	154.9
	MA(100) :	151.27	MA(250) :	139.44
MACD	MACD :	1.4	Signal :	0.9
%K %D	K(14,3) :	88.1	D(3) :	81.6
RSI	RSI(14): 58
52-week	High :	165.42	Low :	109.02

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NVS ] has closed below upper band by 15.8%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	158.61 - 159.67	159.67 - 160.56
Low:	154.39 - 155.44	155.44 - 156.31
Close:	156.89 - 158.61	158.61 - 160.03

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Wed, 29 Jul 2026
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts - ChartMill

Mon, 27 Jul 2026
Berenberg Lifts Price Target on Novartis to $147 From $141, Keeps Hold Rating - Moomoo

Mon, 27 Jul 2026
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180 - Moomoo

Sat, 25 Jul 2026
NVS Stock Price and Chart — NYSE:NVS - TradingView

Thu, 23 Jul 2026
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline - finance.yahoo.com

Wed, 22 Jul 2026
Novartis: The Buy Thesis Is Back (Rating Upgrade) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	1,900 (M)
Shares Float	1,860 (M)
Held by Insiders	0 (%)
Held by Institutions	7.6 (%)
Shares Short	5,710 (K)
Shares Short P.Month	5,250 (K)

EPS	6.61
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	20.18
Profit Margin	22.5 %
Operating Margin	34.6 %
Return on Assets (ttm)	10.2 %
Return on Equity (ttm)	30.3 %
Qtrly Rev. Growth	0.8 %
Gross Profit (p.s.)	22.37
Sales Per Share	29.83
EBITDA (p.s.)	12.15
Qtrly Earnings Growth	-17 %
Operating Cash Flow	18,390 (M)
Levered Free Cash Flow	11,900 (M)

PE Ratio	23.93
PEG Ratio	4.1
Price to Book value	7.85
Price to Sales	5.31
Price to Cash Flow	16.36

Dividend	4.76
Forward Dividend	0
Dividend Yield	3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.